Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis
Michiel Zietse(Erasmus MC), Frederick W. Thielen(University Medical Center Freiburg), Roelof W. F. van Leeuwen(Erasmus MC), Agnes Jager(Erasmus MC Cancer Institute), Ron H.J. Mathijssen(Erasmus MC), Leontine E.A.M.M. Spierings(Alrijne Ziekenhuis), Thirza Kooijman(Erasmus MC), Ruben Malmberg(Erasmus MC)
Cited by 0
Related Papers
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
|PubMed|2001|752
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
|The Lancet Oncology|2018|419
Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|418
Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation
|New England Journal of Medicine|2020|345